Malignant Ascites Treatment Market Size, Share, and Outlook 2026
Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity, particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids. When a...
Ascites is the condition characterized by formation of excessive fluid in the abdominal cavity, particularly in the peritoneal cavity. It causes when the body is unable to eliminate out fluids. When ascites is developed due to cancer, it is called as malignant peritoneal effusion or malignant ascites. Malignancies that are most commonly associated with malignant ascites are cancers of breast, liver, ovary, lungs, lymphoma, and colon. In ascites condition, lymph glands in the body gets blocked and lead to ascites symptoms including low blood pressure, loss of sleep, fatigue, and skin problems.
Click To Continue Reading on Malignant Ascites Treatment Market
Key symptoms in malignant ascites are abdominal pain or discomfort, shortness of breath, swelling of the abdomen, leg or ankle swelling, constipation, and weight gain. Diagnosis of ascites can be done by ultrasound, x-ray test, CT scans, and physical examination. The survival rate of these patients is very low, although with suitable treatment such as paracentesis, chemotherapy, and surgeries are available. Various conventional treatment for malignant ascites include chemotherapy, shunting, paracentesis, and use of drugs such as spironolactone and spironolactone. Cirrhosis of the liver is the most common cause of ascites but other conditions such as kidney failure, heart failure, cancer or infection can also cause ascites.
However, stringent regulations and complications associated with ascites treatment such as internal bleeding after paracentesis treatment, exposure of radiation in chemotherapy may hinder growth of the market over the forecast period. For instance, According to report published in 2017 Experimental & Molecular Medicine showed that radiation can induce toxicities in non-tumorous liver tissues that may limit the course of therapy or have serious chronic side effects, including late fibrosis.
Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1775
PharmaCyte Biotech Inc., Sequana Medical, Fresenius SE & Co. KGaA, BioVie, BD, Medtronic plc, and GI Supply, Actavis Elizabeth LLC, Mylan Pharmaceuticals Inc., GE Healthcare, Trion Pharma, Siemens AG, and Fresenius Biotech.
Visit our news Website: https://www.coherenttimes.org/
Source: Free Articles from ArticlesFactory.com
ABOUT THE AUTHOR
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.